Opdivo (nivolumab) may have specific effects on individuals with liver conditions. In some rare instances, it can lead to liver inflammation and damage, known as hepatitis. This happens because Opdivo can sometimes trigger the immune system to attack healthy tissues, including those in the liver. If hepatitis develops as a result of Opdivo treatment, healthcare providers might decide to temporarily halt or completely stop the infusions. To manage this condition, they may prescribe corticosteroid medications, such as prednisone.
